Genetic Screening & Pre-Pregnancy Tests: What to Know

Genetic carrier screening tells you something prenatal testing can't: your risk of passing on a serious inherited condition, while you still have every reproductive option on the table. This guide covers what carrier screening actually checks, how current guidelines differ, and why timing it before conception rather than after a positive pregnancy test changes what you can do with the results. It sits alongside our pre and post pregnancy services.

This article is for general educational purposes only and does not replace personalised medical or genetic counselling. Carrier screening is entirely voluntary - talk to a genetic counsellor or your provider about what is right for your situation.

In short: genetic carrier screening checks whether you carry a gene variant for a serious inherited condition such as cystic fibrosis, spinal muscular atrophy, sickle cell disease or Tay-Sachs. Done before conception rather than during pregnancy, it gives you the full range of options - from IVF with embryo screening, to early prenatal testing, to donor gametes - instead of a compressed decision timeline mid-pregnancy.

• Carrier screening before conception preserves every reproductive option. Screening during pregnancy compresses decision-making into a much shorter window.
• The ACMG now recommends a population-neutral "Tier 3" panel of 113 genes for everyone, rather than the older approach of testing based on self-reported ethnicity alone.
• An autosomal recessive condition carries a 25% risk to offspring when both partners are carriers. An X-linked condition carries a 50% transmission risk from a carrier mother.
• A negative screen doesn't mean zero risk - residual risk remains because sequencing can miss rare or novel variants.
• MMR and varicella vaccines require a 28-day wait before trying to conceive, since both are live vaccines that are unsafe during an active pregnancy.

Carrier screening is genetic testing that identifies people who carry a single pathogenic gene variant for a recessive or X-linked inherited condition, without having the condition themselves. It is done to estimate the probability of having an affected child - ideally before conception rather than during pregnancy.

Screening before you conceive gives you time for complex decision-making and opens reproductive pathways that simply aren't available once you're already pregnant. If you and your partner are both found to carry a variant in the same gene, or you carry an X-linked variant, options include IVF with pre-implantation genetic testing (PGT-M), which screens embryos before transfer so only unaffected ones are used; using donor gametes from a screened non-carrier; or planning early invasive prenatal testing, with CVS at 10 to 13 weeks or amniocentesis from 15 weeks, if you conceive naturally.

Screening during pregnancy compresses all of this. A positive result means rushing partner testing, urgent genetic counselling and time-sensitive decisions about invasive procedures, all while pregnant. That is the core reason major guidelines now frame preconception as the preferred window, not just an option.

The shift away from ethnicity-based screening reflects a real limitation: self-reported ancestry, and increasingly common interethnic relationships, mean older and narrowly targeted panels miss carriers outside the specific groups they were designed for.

To remove reliance on self-reported race and ancestry, the ACMG organised conditions into four tiers by verified carrier frequency.

For hemoglobinopathies specifically, an MCV under 80 fL or an MCH under 27 pg without iron deficiency triggers HPLC analysis, and a hemoglobin A2 level above 4.0% confirms beta-thalassemia carrier status. For Tay-Sachs, an enzyme assay remains the gold standard at roughly 98% sensitivity across ethnicities, because sequencing alone can miss variants in non-Ashkenazi populations. Pregnant patients and those on oral contraceptives need the leukocyte-based version, since serum assays give false positives in that context.

Population carrier-frequency data underpins the ACMG's Tier 3 threshold: conditions with a carrier frequency of 1 in 200 or greater capture the overwhelming majority of clinically significant recessive disease risk across diverse populations, which is why that threshold - rather than older ancestry-based cutoffs - became the new standard.

For Fragile X specifically, FMR1 repeat-length data defines normal as under 45 CGG repeats, intermediate as 45 to 54, premutation as 55 to 200, and full mutation as over 200. Premutation carriers face real personal risk too, including Fragile X-associated primary ovarian insufficiency, separate from the reproductive risk to potential offspring.

Testing your partner. Sequential testing - screening one partner first, then the other only if the first is positive - saves cost but introduces delay. Concurrent testing of both partners is preferred whenever screening happens during pregnancy or time is limited.

Cascade screening. If you test positive, first- and second-degree relatives share meaningful genetic overlap and face their own elevated carrier probability. Most guidelines recommend giving carriers documentation to share with biological relatives so they can consider screening for their own family planning.

If you and your partner carry the same condition. IVF with PGT-M is an established option. After standard IVF, embryos are cultured to the blastocyst stage, a small trophectoderm biopsy of 5 to 10 cells is taken without disturbing the inner cell mass, and the DNA is analysed to select unaffected embryos for transfer - avoiding the harder decisions that come with prenatal diagnosis of an affected pregnancy.

A complete preconception workup pairs genetic screening with immunity checks for rubella and varicella. Non-immune status for either requires vaccination before conceiving, since maternal infection in the first trimester carries serious risk - congenital rubella syndrome (deafness, cataracts, cardiac defects) or congenital varicella syndrome (microcephaly, limb hypoplasia).

Because MMR and varicella are live vaccines, they're contraindicated during an active pregnancy, and you'll need reliable contraception for at least 28 days after vaccination before trying to conceive. If conception happens sooner than planned, this isn't a reason for concern requiring termination - just a conversation with your provider about the largely theoretical risk. This runs on the same timeline as broader vaccine and nutrient planning before you try to conceive.

Genetic carrier screening is most useful exactly when it's least rushed - before conception, when a positive result still leaves every reproductive pathway open rather than compressing decisions into the middle of a pregnancy. Understanding which panel your provider is offering, what a negative result does and doesn't rule out, and how cascade screening works for your family turns a single test into genuinely informed reproductive planning.

Genetic screening results are not an emergency matter, but if you receive an unexpected positive result, don't wait to schedule genetic counselling. Timely interpretation is what preserves your full range of options.

• PMC - Screening for Autosomal Recessive and X-Linked Conditions (ACMG framework).
• OBG Project - ACMG Recommendations for Preconception and Prenatal Carrier Screening.
• OBG Project - ACOG Opinion on Expanded Carrier Screening.
• ASRM - Prepregnancy Counseling (Committee Opinion).
• CDC - Vaccine Recommendations Before, During and After Pregnancy.